Q1 2025 Management View CEO Kristian Villumsen highlighted 8% organic growth and a reported EBIT margin of 27% for Q1 2025, which aligned with expectations. He emphasized the divestment of the Skin ...

Growth in Interventional Urology was negatively impacted by a voluntary product recall in Bladder Health and Surgery (around DKK 25 million in Q1), partly offset by solid performance in Endourology.

Coloplast AS (CLPBF) reports robust 8% organic growth and a 27% EBIT margin, while addressing challenges in Interventional ...

Shares of Coloplast (CSE:COLOb) climbed 3.5% as the medical device company reported first-quarter revenue in line with ...

as well as costs tied to the Urology recall and skin care exit. The best parts of the Coloplast story remain the company’s strong share in decent markets (35%-plus share in Ostomy, a market ...

Growth in Interventional Urology was negatively impacted by a voluntary product recall in Bladder Health and Surgery (around DKK 25 million in Q1), partly offset by solid performance in Endourology.

Coloplast A/S engages in the development and ... brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal ...